AMRI in pact with Proteros Biostructures
Under the agreement, AMRI will combine its discovery and development capabilities with Proteros’ structural biology services to offer better services to the life sciences industry worldwide. Proteros is
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Tibotec will be responsible for the formulation, manufacturing, registration, distribution and commercialization of the cobicistat and Prezista fixed-dose combination worldwide. Gilead is responsible to develop, manufacture and commercialize